You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
An expanded agreement grants Qiagen a non-exclusive development license to Bio-Techne's exosome technology for the development of companion diagnostic products.
Mount Sinai researchers investigated four cytokine proteins and found that two of them were elevated in the serum samples of SARS-CoV-2 patients who fared the worst.
The firm said that its Diagnostics and Genomics segment sales were essentially flat, while its Protein Sciences segment sales were down 11 percent during Q4.
News items for the week of June 8, 2020.
Bio-Techne said pathologists now have access to its fully automated RNAscope technology, providing them with a new tool to evaluate disease biomarkers.
The Minneapolis-based firm believes the assay can successfully serve as a clinical indicator for patients at risk of developing high-grade prostate cancer (HGPC), thereby improving prostate cancer management.
Customer site shutdowns, particularly in the last several weeks of the quarter, negatively impacted sales by about 3 percent, the firm said.
The reimbursement contract provides about 9 million additional men access to the urine-based, genomic EPI test, Bio-Techne said.
The firm said that in fiscal Q2, its China businesses continued to achieve greater than 20 percent growth, but its European business growth was soft year over year.
AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.
According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.
Time magazine looks into how liquid biopsies are changing cancer care.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.